{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2.5+mg+Olanzapine",
    "query": {
      "intervention": "2.5 mg Olanzapine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=2.5+mg+Olanzapine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T21:04:54.278Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06133114",
      "title": "Psychopharmacological Treatment of Emotional Distress",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Suicide Crisis Syndrome",
        "Psychological Distress"
      ],
      "interventions": [
        {
          "name": "Clonazepam",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-03-13",
      "completion_date": "2024-03-13",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06133114"
    },
    {
      "nct_id": "NCT06588413",
      "title": "Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Autologous Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2024-09-17",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06588413"
    },
    {
      "nct_id": "NCT05179772",
      "title": "Olanzapine in OUD Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-07-28",
      "completion_date": "2023-01-30",
      "has_results": false,
      "last_update_posted_date": "2023-02-01",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Richmond, Virginia",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179772"
    },
    {
      "nct_id": "NCT07581405",
      "title": "GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-09",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07581405"
    },
    {
      "nct_id": "NCT01617200",
      "title": "Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Asenapine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Asenapine",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2012-12",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-05-27",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617200"
    },
    {
      "nct_id": "NCT00186017",
      "title": "Short Term Rescue Study of Olanzapine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Olanzapine/Zyprexa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-07",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00186017"
    },
    {
      "nct_id": "NCT00000374",
      "title": "Treatment for First-Episode Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 125,
      "start_date": "1998-09",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-01-13",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 2,
      "location_summary": "Glen Oaks, New York • The Bronx, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000374"
    },
    {
      "nct_id": "NCT03030417",
      "title": "Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "LMP744",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "OTHER"
        },
        {
          "name": "Olanzapine",
          "type": "OTHER"
        },
        {
          "name": "Lorazepam",
          "type": "OTHER"
        },
        {
          "name": "Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate",
          "type": "OTHER"
        },
        {
          "name": "Loperamide",
          "type": "OTHER"
        },
        {
          "name": "Diphenhydramine",
          "type": "OTHER"
        },
        {
          "name": "Steroid",
          "type": "OTHER"
        },
        {
          "name": "Epinephrine",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2017-02-27",
      "completion_date": "2023-10-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03030417"
    },
    {
      "nct_id": "NCT00489593",
      "title": "Olanzapine in Patients With Advanced Cancer and Weight Loss",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 57,
      "start_date": "2006-10",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489593"
    },
    {
      "nct_id": "NCT00057408",
      "title": "A Controlled Study of Olanzapine in Children With Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autistic Disorder"
      ],
      "interventions": [
        {
          "name": "olanzapine (Zyprexa)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FDA Office of Orphan Products Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 78,
      "start_date": "2003-05",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-09-26T21:04:54.278Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00057408"
    }
  ]
}